Aug 14, 2026 · 18 min · 11 segments
Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from…
Preeti MalaniHost
Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer comprises the vast majority of these cases.
Epidermal growth factor receptor, or EGFR, mutations are common, and third-generation EGFR tyrosine kinase inhibitors like osimertinib are the global standard first-line treatment for patients with advanced non-small cell lung cancer with EGFR mutations.
In a new study, Dr. Sho and colleagues asked whether patients with concurrent TP53 mutations, a high-risk subgroup, do better with first-line osimertinib plus chemotherapy than osimertinib alone in a phase three trial.
The investigators enrolled two hundred and ninety-four treatment-naive patients at 17 sites in China.
The median progression-free survival was thirty-four months with combination therapy versus fifteen point six months with monotherapy.
That is an eighteen-month difference, and it was consistent across pre-specified groups, including patients with brain metastases.
Response rates were also higher, eighty-two point nine percent versus seventy-one point six percent.
Grade three or higher treatment-related adverse events occurred in sixty-two point four percent with the combination therapy versus fourteen point nine percent with monotherapy.
Overall survival data is still immature, but these results support a more individualized TP53-guided approach to first-line treatment for patients with non-small cell lung cancer and an EGFR mutation.
In an accompanying editorial, Dr. Bourgeat and colleagues say this study strengthens the case for treatment intensification in this molecularly defined high-risk population.
They also caution that the toxicity burden of combination therapy is real, and notably, quality of life worsened early during combination therapy.
The editorial authors also highlight that more prospective trials are needed to help determine which patients can avoid the risks associated with treatment intensification.
Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer comprises the vast majority of these cases.
Epidermal growth factor receptor, or EGFR, mutations are common, and third-generation EGFR tyrosine kinase inhibitors like osimertinib are the global standard first-line treatment for patients with advanced non-small cell lung cancer with EGFR mutations.
In a new study, Dr. Sho and colleagues asked whether patients with concurrent TP53 mutations, a high-risk subgroup, do better with first-line osimertinib plus chemotherapy than osimertinib alone in a phase three trial.
The investigators enrolled two hundred and ninety-four treatment-naive patients at 17 sites in China.
The median progression-free survival was thirty-four months with combination therapy versus fifteen point six months with monotherapy.
That is an eighteen-month difference, and it was consistent across pre-specified groups, including patients with brain metastases.
Response rates were also higher, eighty-two point nine percent versus seventy-one point six percent.
Grade three or higher treatment-related adverse events occurred in sixty-two point four percent with the combination therapy versus fourteen point nine percent with monotherapy.
Overall survival data is still immature, but these results support a more individualized TP53-guided approach to first-line treatment for patients with non-small cell lung cancer and an EGFR mutation.
In an accompanying editorial, Dr. Bourgeat and colleagues say this study strengthens the case for treatment intensification in this molecularly defined high-risk population.
They also caution that the toxicity burden of combination therapy is real, and notably, quality of life worsened early during combination therapy.
The editorial authors also highlight that more prospective trials are needed to help determine which patients can avoid the risks associated with treatment intensification.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
